Form 4: Recursion Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Najat Khan, CEO and President and a Director of Recursion Pharmaceuticals, Inc., reported a transaction in 80,498 shares of common stock on August 17, 2026.
Summary
- Tax/exercise-price withholding: disposed of 80,498 Class A Common Stock at $3.16 ($254,374) on August 17, 2026; holds 2,095,298 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Najat Khan — Director, Officer (CEO and President)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Tax/exercise-price withholding | Class A Common Stock | 80,498 | $3 | $254.4K | 2,095,298 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Tax/exercise-price withholding (80,498 shares) |
Keywords
insider transaction, Form 4, RXRX, RECURSION PHARMACEUTICALS, INC., neutral, Najat Khan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.